Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScience Sprt Regulatory News (SIS)

  • This share is currently suspended. It was suspended at a price of 33.50
  • There is currently no data for SIS

Trading Statement

30 Jan 2025 07:00

RNS Number : 1960V
Science in Sport PLC
30 January 2025
 

Science in Sport plc

("Science in Sport", "the Company" or the "Group")

 

Trading update - Unaudited pre-close statement

FY24 results exceed market expectations with a strengthened balance sheet

Science in Sport plc (AIM: SIS), the premium performance nutrition company serving elite athletes, sports enthusiasts, and the active lifestyle community, is pleased to announce an unaudited trading update in respect of the financial year ended 31 December 2024 ("FY24") and the outlook for 2025.

The Board is pleased to report that the Group's unaudited results for FY24, including Adjusted EBITDA and Net Debt, are expected to be ahead of current market expectations by reporting:

Key Financials (unaudited):

 

Full Year Comparisons

Half Year Comparisons

 

FY24

FY23

Change

FY24 H2

FY24 H1

Change

Revenue

£51.9m

£62.8m

(17.5%)

£26.2m

£25.7m

+1.9%

Adjusted EBITDA

£4.2m

£2.0m

+105.0%

£2.2m

£2.0m

+10.0%

Net Debt

£5.9m

£12.9m

+£7.0m

£5.9m

£13.8m

+£7.9m

Since the Interim Results were announced on 16 September 2024 the Group has continued to see improvements in its operational and financial performance, gaining further traction on returning to profitable growth from a stronger operating platform, with a significantly reduced cost base as well as improving operating margins and cash generation dynamics. Gross margins have continued to improve throughout FY24 to in excess of c.45% (FY23: c.43%). As previously announced, the reset of the operating model undertaken by the new leadership team is now well underway and is underpinning the improved performance, particularly in FY24 H2 where the Group returned to growth, which is anticipated to continue into FY25.

FY25 Outlook

Trading has started well and we expect the return to growth seen in FY24 H2 to continue in to FY25 together with the full effects of the cost savings made in FY24. The strategic focus areas are driving profitable revenue growth through distribution agreements both domestically and internationally; controlled growth over the medium term supported by effective marketing with clear commercial execution; and, continued margin improvements from disciplined pricing and an ongoing focus on cost and operational change resulting in cash generation to deleverage and re-invest for growth. Management's confidence in targeting a 15% EBITDA business earlier than previously anticipated is increased.

 

 

For further information:

Science in Sport plc

T: +44 (0) 20 7400 3700

Daniel Wright, Executive Chairman

Daniel Lampard, Chief Operating Officer

Christopher Welsh, Chief Financial Officer

Panmure Liberum Limited (Nominated Adviser and Broker)

T: +44 (0) 20 3100 2000

Richard Lindley

John More

 

Notes to Editors

About Science in Sport plc

Headquartered in London, Science in Sport plc is a leading sports nutrition business that develops, manufactures, and markets innovative nutrition products for professional athletes, sports and fitness enthusiasts and the active lifestyle community. The Company has two highly regarded brands, PhD Nutrition, a premium active-nutrition brand targeting the active lifestyle community, and SiS, a leading endurance nutrition brand among elite athletes and professional sports teams.

The two brands sell through the Company's phd.com and scienceinsport.com digital platforms, third-party online sites, including Amazon and ebay, and extensive retail distribution in the UK and internationally, including major supermarkets, high street chains and specialist sports retailers. This omnichannel footprint enables the Company to address the full breadth of the sports nutrition market.

PhD is one of the UK's leading active nutrition brands with a reputation for high quality and product innovation. The brand has grown rapidly since its launch in 2005. The range now comprises powders, bars, and supplements, including the high protein, low sugar range, PhD Smart.

SiS, a leading endurance nutrition business founded in 1992, has a core range comprising gels, powders and bars focused on energy, hydration, and recovery. SiS is an official endurance nutrition supplier to over 320 professional teams, organisations, and national teams worldwide. SiS supplies more than 150 professional football clubs in the UK, Europe, and the USA. 

For further information, please visit phd.com and scienceinsport.com

 

1 Earnings before interest, tax, depreciation, amortisation, share-based payments and foreign exchange variance on intercompany balances, restructuring costs, transition costs and material one-off items

2 Net debt is defined as cash, less banking working capital facilities and asset financing and excludes property leases

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFZGZMGLLGKZZ
Date   Source Headline
30th Sep 20227:00 amRNSInterim Results
16th Sep 20227:00 amRNSDirectorate Change
11th Aug 20229:00 amRNSPrice Monitoring Extension
25th Jul 20224:45 pmRNSBroker Update
8th Jul 202211:05 amRNSSecond Price Monitoring Extn
8th Jul 202211:00 amRNSPrice Monitoring Extension
8th Jul 20227:00 amRNSHalf-Year Trading Update
15th Jun 20224:27 pmRNSResult of AGM
9th Jun 20227:00 amRNSBoard Change
12th May 202211:06 amRNSTR-1: Notification of Major Holdings
9th May 20227:00 amRNSNotice of AGM
5th May 202211:32 amRNSTR-1: Notification of Major Holdings
4th May 20227:00 amRNSPartnership With New York Marathon and NYRR
29th Apr 20227:00 amRNSGrant of Options, Adoption of New LTIP and TVR
28th Apr 20227:00 amRNSBreakthrough Sports Science Technology Study
21st Apr 20222:16 pmRNSTR-1: Notification of Major Holdings
8th Apr 20222:34 pmRNSTR-1: Notification of major holdings
8th Apr 20221:47 pmRNSTR-1: Notification of major holdings
29th Mar 20227:39 amRNSFinal Results
17th Mar 20227:00 amRNSInvestor Presentation
15th Mar 20227:00 amRNSDate of Final Results
10th Mar 20227:00 amRNSInvestor Presentation
22nd Feb 202211:27 amRNSTR-1: Notification of Major Holdings
22nd Feb 202211:24 amRNSTR-1: Notification of Major Holdings
24th Jan 20225:49 pmRNSHolding(s) in Company
19th Jan 20227:00 amRNSTrading Update
5th Jan 20227:00 amRNSAppointment of Joint Broker
4th Jan 20224:51 pmRNSHolding(s) in Company
7th Oct 20213:12 pmRNSHolding(s) in Company
29th Sep 20217:00 amRNSPartnership with Milwaukee Bucks
15th Sep 20217:00 amRNSInterim Results
9th Sep 20217:00 amRNSInvestor Presentation
2nd Aug 20217:00 amRNSNew PhD Nutrition 'Life' Range
19th Jul 20217:00 amRNSLaunch of new category-leading product range
14th Jul 20217:00 amRNSHalf Year Trading Update
24th Jun 20213:44 pmRNSResult of AGM
22nd Jun 20213:10 pmRNSHolding(s) in Company
21st Jun 202110:57 amRNSHolding(s) in Company
20th May 20217:00 amRNSNotice of AGM
19th May 202112:59 pmRNSNotification of Major Holdings
10th May 20215:10 pmRNSPDMR Share Purchases
10th May 20217:00 amRNSExtends Partnership with INEOS Grenadiers
28th Apr 202111:01 amRNSPDMR Share Purchases
18th Mar 20212:34 pmRNSNotification of Major Holdings
17th Mar 20217:00 amRNSFinal Results
11th Mar 20217:00 amRNSInvestor Presentation
5th Feb 202112:50 pmRNSNotification of Major Holdings
1st Feb 20211:59 pmRNSHolding(s) in Company
28th Jan 20217:00 amRNSCapital Markets Day
15th Jan 20212:06 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.